Table 2 Incidence, most common AEs, chest-related AEs in placebo-controlled RCTs after oral administration of zolmitriptan 2.5 mg [15, 33]
Placebo (n = 401) (%) | Zolmitriptan 2.5 mg (n = 498) (%) | |
|---|---|---|
Patients with at least one AE | 117 (29) | 227 (46) |
Most common AEs | ||
Asthenia | 13 (3) | 16 (3) |
Dry mouth | 7 (2) | 16 (3) |
Nausea | 15 (4) | 45 (9) |
Dizziness | 16 (4) | 42 (8) |
Somnolence | 12 (3) | 30 (6) |
Paresthesia | 6 (1) | 21 (4) |
Warm sensitation | 7 (2) | 21 (4) |
Chest-related AEs | ||
Chest tightness | 2 (<1) | 13 (3) |
Chest pain | 1 (<1) | 1 (1 < 1) |
Chest heaviness | 0 (0) | 1 (<1) |
Chest pressure | 1 (<1) | 1 (<1) |